5 articles in this issue
Federico Vancheri,Pompilio Faggiano,Michael Y Henein
The burden of cardiovascular disease in developed countries has shown dramatic improvements over the last 50 years, largely due the identification and control of major risk factors including, smoking hypertension and high cholesterol. However,... see more
Andrew Coats
The VICTORIA trial showed Vericiguat once daily (titrated up to 10 mg) significantly reduced its primary end-point, the composite of death from cardiovascular causes or first hospitalization for heart failure, in 5050 class II-IV HFrEF patients (LVEF<4... see more
Pompilio Faggiano,Giuseppe Patti,Stefania Cercone,Laura Canullo,Roberta Rossini,Gian Piero Perna,Angela Pirillo,Francesco Fattirolli,Gianfranco Terrosu,Pier Luigi Temporelli,Alberico Catapano
PURPOSE: Patients suffering from an acute coronary syndrome are at very high risk for recurrent events. Early targeted pharmacological intervention primarily aimed at controlling plasma LDL-cholesterol (LDL-C) levels can result in the reduction of re... see more
Alexander Manché,Liberato Camilleri
Background: Transfusion is common after coronary bypass surgery. Transfused patients present with higher operative risk and increased hazard ratio for curtailed long-term survival. There is debate as to whether transfusion itself may further exacerbate la... see more
Mark Christopher Arokiaraj
Background: The purpose was to develop a novel hypothetical method to increase the size of coronary arteries.Methods: During long-term observation an increase in coronary size has been seen in three unexpected scenarios. Changes in coronary arte... see more